Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04982393 · ClinicalTrials.gov registry record
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
A clinical trial of Primary Hyperoxaluria Type 1, sponsored by Alnylam Pharmaceuticals.
- Active
- Registry status
- 207
- Enrollment target
- 20
- Study locations
NCT04982393: Active study of Primary Hyperoxaluria Type 1, sponsored by Alnylam Pharmaceuticals.
NCT04982393 is a study of Primary Hyperoxaluria Type 1 that is active but no longer recruiting, run by Alnylam Pharmaceuticals. The registered enrollment target is 207 participants. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04982393, a study of Primary Hyperoxaluria Type 1, is active but no longer recruiting, sponsored by Alnylam Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 207 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
Conditions Studied
Study Locations (20)
Other
- Clinical Trial Site - Ghent
- Clinical Trial Site - Liège
- Clinical Trial Site - Bordeaux
- Clinical Trial Site - Lyon
- Clinical Trial Site - Paris
- Clinical Trial Site - Berlin
- Clinical Trial Site - Cologne
- Clinical Trial Site - Hamburg
- Clinical Trial Site - Jerusalem
Texas
- Clinical Trial Site - Dallas
- Clinical Trial Site - Houston
Ontario
- Clinical Trial Site - Hamilton
- Clinical Trial Site - Toronto
Arizona
- Clinical Trial Site - Phoenix
District of Columbia
- Clinical Trial Site - Washington D.C.
Massachusetts
- Clinical Trial Site - Boston
Minnesota
- Clinical Trial Site - Rochester
Ohio
- Clinical Trial Site - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2028-09-01 |
What the registry record for NCT04982393 still lists
NCT04982393 is an observational study that tracks outcomes without assigning an intervention. The registered 207 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Primary Hyperoxaluria Type 1 appearing as the primary indexed condition, and to 0 interventions.
NCT04982393 names 20 study sites across 10 states, led by Other, Texas, Ontario.
Frequently Asked Questions
What is clinical trial NCT04982393 about?
NCT04982393 is a clinical study titled "BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)". The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
What is the current status of trial NCT04982393?
This trial is currently active not recruiting. The enrollment target is 207 participants. The study started on 2021-12-13. Estimated completion is 2028-09-01.
What conditions does trial NCT04982393 study?
This clinical trial studies the following conditions: Primary Hyperoxaluria Type 1.
Who is sponsoring clinical trial NCT04982393?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04982393 being conducted?
This trial has 20 study locations across Arizona, District of Columbia, Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Hyperoxaluria Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04353778 · 207 participants · Phase 1
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
- NCT05875805 · 207 participants · NA
A Telehealth Advance Care Planning Intervention
- NCT06254950 · 207 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
- NCT06904274 · 207 participants · Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI